Today

Agents

Chat

Arena

Discover

More

App

Alnylam Pharmaceuticals Q2 Adjusted EPS USD 1.84 Vs. IBES Estimate USD 1.55 - ALNY News | Rallies

Alnylam Pharmaceuticals Q2 Adjusted EPS USD 1.84 Vs. IBES Estimate USD 1.55

ALNY•2026-07-30

Q2 earnings and revenue

Jul 30 (Reuters) - Alnylam Pharmaceuticals Q2 revenue USD 1,290.948 million vs. IBES estimate USD 1,323 million.

Q2 adjusted net income USD 251.801 million
Q2 adjusted operating income USD 318.066 million
Q2 operating income USD 231.441 million
Q2 net income USD 164.494 million

Related News

Amgen says EU CHMP backs broader Repatha use to cut first heart attack, stroke risk

AMGN•2026-07-30

PAVmed unit Lucid Diagnostics schedules Q2 2026 business update call for Aug. 13

LUCD•2026-07-30

Phunware names Nick Farrell senior vice president of sales

•

2026-07-30

Cemtrex subsidiary Vicon wins about $900,000 US corrections facility security order

CETX•2026-07-30

KKR profit leaps as private equity deals flourish

KKR•2026-07-30